DoubleRainbow Biosciences Inc.
Evolved medicines created through directed evolution and synthetic biology approaches
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2017
- Latest Form D
- $10M, Nov 2020
- Total capital
- $15M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $15M
- 3 Form D · last Nov 2020
- 72 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$10M
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Jiangtao YuDirectorNamed in SEC Form D filings
- Jing-Ke WengDirectorNamed in SEC Form D filings
- John YuDirectorNamed in SEC Form D filings
- Tian XuDirectorNamed in SEC Form D filings
- Wan YuExecutive OfficerNamed in SEC Form D filings
- Wei GongExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- PendingEtoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer DrugUSPTOApplication 17906373
- PendingIvacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic FibrosisUSPTOApplication 17906396
- PendingMethod For Producing Glycosylated Therapeutics By Using An Immobilized Enzyme PreparationUSPTOApplication PCTUS2022076462
Show all 12 patent records
- Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer DrugJun 22, 2023 · Application 17906373Pending
- Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic FibrosisApr 20, 2023 · Application 17906396Pending
- Method For Producing Glycosylated Therapeutics By Using An Immobilized Enzyme PreparationApplication PCTUS2022076462Pending
- Method For Producing Glycosylated Therapeutics by Using an Immobilized Enzyme PreparationApplication 63245723Pending
- Use of Cyclodextrin to Enhance Solubility of Substrates and Increase Enzymatic Glycosylation Reaction EfficiencyApplication 63245671Pending
- Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-cancer DrugApplication PCTUS2021022414Pending
- Enasidenib Glycosides, Methods Of Making, And Uses Thereof In Treating Acute Myeloid Leukemia And Other Diseases Associated With Isocitrate Dehydrogenase (idh) DysfunctionApplication PCTUS2021022410Pending
- Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic FibrosisApplication PCTUS2021022416Pending
- Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic FibrosisApplication 62990101Pending
- Enasidenib Glycosides, Methods Of Making, And Uses Thereof In Treating Acute Myeloid Leukemia And Other Diseases Associated With Isocitrate Dehydrogenase (IDH) DysfunctionApplication 62990114Pending
- Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer DrugApplication 62990124Pending
- Use Of Cyclodextrin To Enhance Solubility Of Substrates And Increase Enzymatic Glycosylation Reaction EfficiencyApplication PCTUS2022076459Pending
Related companies, and why
- Endogena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SystImmune, Inc.Similar federal contract value in Biotech · null in contracts
- Paragon Biosciences Qlarity Capital, Inc.Similar federal contract value in Biotech · null in contracts
- NANOVIRICIDES, INC.Similar federal contract value in Biotech · null in contracts
- Causeway Therapeutics LtdSimilar federal contract value in Biotech · null in contracts
- Carmine Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .